9-ING-41 in Pediatric Patients With Refractory Malignancies.

Active:	No
Cancer Type:	Brain & Spinal Cord Tumor Hematopoietic Malignancies Lymphoma Neuroblastoma	NCT ID:	NCT04239092
Trial Phases:	Phase I	Protocol IDs:	1902 (primary) NCI-2020-04584
Eligibility:	0 - 22 Years, Male and Female	Study Type:	Treatment
Study Sponsor:	Actuate Therapeutics Inc.
NCI Full Details:	http://clinicaltrials.gov/show/NCT04239092

Summary

9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients.
This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.

Objectives

9-ING-41 is a first-in-class, intravenously administered, maleimide-based, small molecule,
potent selective GSK-3ß inhibitor with significant pre-clinical and clinical anticancer
activity. In the ongoing Actuate 1801 study in a cohort of over 90 patients with advanced
refractory malignancies, 9-ING-41 has exhibited no significant toxicity, including no
myelosuppression, and significant anti-tumor activity. 9-ING-41 also has significant
pre-clinical ability to reverse pathologic fibrosis in multiple models of pulmonary and
pleural fibrosis. 9-ING-41 is very highly active against neuroblastoma in diverse
pre-clinical models. This Phase 1 study is designed to evaluate the safety and efficacy of
9-ING-41, as a single agent or in combination with irinitecan, in paediatric patients with
advanced malignancies and thus to establish the recommended Phase 2 dose (RP2D) for further
paediatric patient studies.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.